breast-pathology-2017-posters-accepted-abstracts

Page 66

conferenceseries

.com

Volume 2, Issue 4 (Suppl)

Breast Can Curr Res, an open access journal

Breast Pathology 2017

August 23-24, 2017

August 23-24, 2017 Toronto, Canada

World Congress on

Breast Pathology and Cancer Diagnosis

Breast Can Curr Res 2017, 2:4 (Suppl)

DOI: 10.4172/2572-4118-C1-009

A novel handheld diffuse optical breast cancer imaging probe

Majid Shokoufi and Farid Golnaraghi

Simon Fraser University, Canada

iffuse optical spectroscopy (DOS) and diffuse optical imaging (DOI) are relatively new methods for breast cancer

diagnosis which are noninvasive and nonionizing techniques. In the present study, we have introduced a novel handheld

diffuse optical breast scanning (DOB-Scan) probe to measure optical properties of breast tissue and create functional and

compositional cross-sectional images of the breast. Four near-infrared wavelengths light emitting diodes (LED), encapsulated

in a package (eLED), are used to illuminate the breast tissue. A linear charge coupled device (CCD) measures the intensity

of the scattered photons at different radial destinations from the illumination source on the surface of the breast tissue. The

proposed method replaces fiber optic based illumination techniques, which increases the complexity, size and cost of a

potential probe, by multi-wavelengths eLED which acts as a pencil beam source in such a scattering media like the breast tissue.

Although the introduced technique miniaturizes the probe, this study points to the reliability and accuracy of this technique

in breast imaging. The average scattering coefficient of the medium and localized concentration variations in oxyhemoglobin

and deoxyhemoglobin can be measured utilizing the probe. In order to evaluate the performance of DOB-scan probe, a series

of tissue-like materials, containing of Intralipid®, Black ink, Delrin®, and PierceTM have been used. We have received ethical

approvals to test the DOB-scan probe on patients who are known with breast cancer and we are currently testing the DOB-scan

probe on real subjects.